Takeda to Gain Selective PI3K and mTOR Inhibitors via Intellikine Acquisition

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 9 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1653     ISSN: 1756-7874

Section: Mergers & Acquisitions



Via its US subsidiary Takeda America Holdings, Takeda Pharmaceutical has moved to strengthen its oncology pipeline by agreeing to acquire Intellikine for up to US$310 M, including US$190 M in cash upfront and up to US$120 M in potential clinical development milestone payments...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details